Medivir has a leading competence within protease inhibitor design and nucleotide/nucleoside science and the company is dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir’s commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
- Bli medlem
- Om SwedenBIO